Skip to main content
Deutsches Ärzteblatt International logoLink to Deutsches Ärzteblatt International
letter
. 2017 Mar 17;114(11):192. doi: 10.3238/arztebl.2017.0192b

Correspondence (letter to the editor): Pregabalin: Risk of Addiction and Misuse

Karlheinz Hoffmann *
PMCID: PMC5387853  PMID: 28382907

I would like to add that the risks of drug dependence, addiction and misuse are not limited to opiates/opioids, but must be taken into consideration with the first-line drug pregabalin as well. In parts of the drug scene, pregabalin is consumed in significant amounts and with severe negative consequences (behavioral changes in some cases similar to those seen with benzodiazepines and lethal [mixed] intoxications, among others).

While it may be acceptable to prescribe pregabalin to patients who are known to the physician for many years and have their diagnosis adequately confirmed, I think that pregabalin should not be prescribed to unknown patients (“recently moved to the area”, “family physician cannot be contacted“, “on holiday and pregabalin package accidentally left at home“) without verification of the information provided by the patient. Unfortunately, the broad range of indications, extending beyond neuropathic pain, promotes doctor hopping for the purpose of acquiring pregabalin.

Footnotes

Conflict of interest statement

The author declares that no conflict of interest exists.

References

  • 1.Binder A, Baron R. The pharmacological therapy of chronic neuropathic pain. Dtsch Arztebl Int. 2016;113:616–626. doi: 10.3238/arztebl.2016.0616. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Deutsches Ärzteblatt International are provided here courtesy of Deutscher Arzte-Verlag GmbH

RESOURCES